Drugs / AVI-5126
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00451256 | Mar → Nov 2007 | coronary artery disorder | Sarepta Therapeutics, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2007-07-25 | Sarepta Therapeutics, Inc. | Results AVI BioPharma Partner Global Therapeutics Announces Positive Pre-Clinical Results Shown Using NEUGENE Antisense Drug in Prevention of Cardiovascular Restenosis sarepta.com ↗
Global Therapeutics noted that the studies showed successful safe delivery of a therapeutic dose of the antisense agent to the specific site of stenting, with no systemic adverse events. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2007-07-25 | Sarepta Therapeutics, Inc. | AVI BioPharma Partner Global Therapeutics Announces Positive Pre-Clinical Results Shown Using NEUGENE Antisense Drug in Prevention of Cardiovascular Restenosis sarepta.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVI-5126 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00451256 ↗ |
| Action | Inhibit | “to inhibit the c-myc gene” NCT00451256 ↗ |
| Modality | Antisense oligonucleotide | “novel anti-c-myc antisense drug” NCT00451256 ↗ |
| Route | Other | “immersion of the excised saphenous vein in a novel anti-c-myc antisense drug (AVI-5126) solution” NCT00451256 ↗ |
| Target | MYC | “to inhibit the c-myc gene” NCT00451256 ↗ |